Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
For the full year,net profit rose 18.64% to Rs 595.02 crore in the year ended March 2026 as against Rs 501.52 crore during the previous year ended March 2025. Sales rose 19.81% to Rs 5338.92 crore in the year ended March 2026 as against Rs 4455.97 crore during the previous year ended March 2025.
EBITDA stood at Rs 352.1 crore in Q4 FY26, registering the growth of 40%, compared with Rs 252.4 crore in Q4 FY25.EBITDA margin improved to 24% in Q4 FY26 as against 21% in Q4 FY25.
Revenue from operations in Q4 FY26 was driven by finished dosages (FD) at 73%, followed by active pharmaceutical ingredients (API) at 13%, pharmaceutical formulation intermediates (PFI) at 9%, and peptide/CDMO at 5%.
On a full-year basis, the company’s consolidated net profit climbed 18.65% to Rs 595.02 crore on 19.73% increase in revenue from operations to Rs 5365.64 crore in FY26 over FY25.
Krishna Prasad Chigurupati, chairman & managing director of Granules India said, “We delivered a strong performance in Q4FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. The quarter reflects improving earnings quality and sustained advancement in Complex Generics and the Peptides CDMO platform.”
Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).
Granules India announced that its US step-down subsidiary, Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc. has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) Status from the US Food and Drug Administration (FDA).
The FDA inspection was conducted at the company's packaging facility in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility's second FDA inspection, following the March 2023 audit, which also concluded with zero observations.
The FDA inspection was conducted at the company’s packaging facility in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility’s second FDA inspection, following the March 2023 audit, which also concluded with zero observations.
Krishna Prasad Chigurupati, chairman and managing director of Granules India, said, “Granules Consumer Health plays a critical role in our global operations as a packaging and distribution site. We process controlled substances and over-the-counter (OTC) products across three advanced packaging lines. Achieving zero observations in this inspection reflects the strong culture of quality, safety and regulatory excellence demonstrated by our teams.”
Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company reported a 27.73% jump in consolidated net profit to Rs 150.21 crore on 22% increase in revenue from operations to Rs 1,387.94 crore in Q3 FY26 over Q3 FY25.
Profit before tax (PBT) jumped 32.36% YoY to Rs 202.23 crore during the quarter.
EBITDA stood at Rs 308.1 crore, registering the growth of 34% compared with Rs 230.3 crore in Q3 FY25. EBITDA margin improved to 22% in Q3 FY26 as against 20% in Q3 FY25.
For Q3 FY26, Finished Dosages, Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/CDMO contributed 76%, 11%, 11%, and 2% of revenue from operations, respectively.
Net debt stood at Rs 1,015.1 crore and Net debt to EBITDA at 0.91x in Q3 FY26.
Krishna Prasad Chigurupati, chairman & managing director of Granules India said, “Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, on-going R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders.”
The scrip declined 1.09% to end at Rs 564.95 on the BSE.